Concert Pharmaceuticals’ (CNCE) “Buy” Rating Reiterated at Stifel Nicolaus

Stifel Nicolaus reissued their buy rating on shares of Concert Pharmaceuticals (NASDAQ:CNCE) in a report released on Friday. Stifel Nicolaus currently has a $27.00 price target on the biotechnology company’s stock.

CNCE has been the topic of several other reports. Zacks Investment Research lowered Concert Pharmaceuticals from a hold rating to a sell rating in a report on Tuesday, October 24th. BidaskClub upgraded Concert Pharmaceuticals from a buy rating to a strong-buy rating in a research report on Saturday, December 9th. UBS Group set a $34.00 target price on Concert Pharmaceuticals and gave the company a buy rating in a research report on Tuesday, December 19th. TheStreet upgraded Concert Pharmaceuticals from a c+ rating to a b- rating in a research report on Monday, January 8th. Finally, HC Wainwright restated a buy rating and issued a $20.00 target price on shares of Concert Pharmaceuticals in a research report on Monday, September 18th. Three equities research analysts have rated the stock with a hold rating and five have issued a buy rating to the stock. The company presently has a consensus rating of Buy and an average target price of $24.33.

Shares of Concert Pharmaceuticals (NASDAQ CNCE) traded down $7.53 on Friday, reaching $20.15. Concert Pharmaceuticals has a 12 month low of $8.61 and a 12 month high of $30.71. The firm has a market cap of $458.85, a price-to-earnings ratio of 5.37 and a beta of 1.67.

Concert Pharmaceuticals (NASDAQ:CNCE) last issued its quarterly earnings data on Thursday, November 9th. The biotechnology company reported ($0.70) EPS for the quarter, missing the consensus estimate of ($0.54) by ($0.16). Concert Pharmaceuticals had a net margin of 62.31% and a negative return on equity of 51.48%. research analysts anticipate that Concert Pharmaceuticals will post 4.1 earnings per share for the current year.

In other news, Director Ronald W. Barrett sold 14,156 shares of the firm’s stock in a transaction that occurred on Monday, December 4th. The stock was sold at an average price of $24.70, for a total value of $349,653.20. Following the transaction, the director now owns 3,539 shares in the company, valued at $87,413.30. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, insider Value Fund L. P. Biotechnology sold 1,282,856 shares of the firm’s stock in a transaction that occurred on Tuesday, December 19th. The shares were sold at an average price of $26.65, for a total value of $34,188,112.40. The disclosure for this sale can be found here. Company insiders own 10.10% of the company’s stock.

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Vanguard Group Inc. lifted its position in Concert Pharmaceuticals by 11.0% during the second quarter. Vanguard Group Inc. now owns 756,513 shares of the biotechnology company’s stock worth $10,553,000 after buying an additional 74,801 shares in the last quarter. Northern Trust Corp lifted its position in Concert Pharmaceuticals by 11.2% during the second quarter. Northern Trust Corp now owns 243,989 shares of the biotechnology company’s stock worth $3,403,000 after buying an additional 24,622 shares in the last quarter. Point72 Asset Management L.P. purchased a new position in Concert Pharmaceuticals during the third quarter worth approximately $843,000. State Street Corp lifted its position in Concert Pharmaceuticals by 9.5% during the second quarter. State Street Corp now owns 300,093 shares of the biotechnology company’s stock worth $4,186,000 after buying an additional 26,024 shares in the last quarter. Finally, Schwab Charles Investment Management Inc. lifted its position in Concert Pharmaceuticals by 47.9% during the second quarter. Schwab Charles Investment Management Inc. now owns 32,122 shares of the biotechnology company’s stock worth $449,000 after buying an additional 10,400 shares in the last quarter. Institutional investors and hedge funds own 65.29% of the company’s stock.

TRADEMARK VIOLATION NOTICE: “Concert Pharmaceuticals’ (CNCE) “Buy” Rating Reiterated at Stifel Nicolaus” was first published by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are viewing this piece of content on another website, it was illegally stolen and reposted in violation of international copyright & trademark laws. The legal version of this piece of content can be accessed at https://www.dispatchtribunal.com/2018/01/15/concert-pharmaceuticals-cnce-buy-rating-reiterated-at-stifel-nicolaus.html.

Concert Pharmaceuticals Company Profile

Concert Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company is engaged in the discovery and development of small molecule drugs. The Company operates through the development of pharmaceutical products on its own behalf or in collaboration with others. The Company’s deuterated chemical entity platform (DCE Platform), has potential across various therapeutic areas.

Receive News & Ratings for Concert Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Concert Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply